Press Releases
May 20, 2022
TFF Pharmaceuticals to Participate at the H.C. Wainwright Global Investment Conference
TFF Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business UpdateMay 11, 2022
TFF Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
TFF Pharmaceuticals Announces Multiple Presentations Highlighting Broad Applicability of its Thin Film Freezing Technology at Respiratory Drug Delivery Meeting (RDD)May 2, 2022
TFF Pharmaceuticals Announces Multiple Presentations Highlighting Broad Applicability of its Thin Film Freezing Technology at Respiratory Drug Delivery Meeting (RDD)
TFF Pharmaceuticals to Hold First Quarter 2022 Financial and Business Results Conference Call on May 11, 2022April 29, 2022
TFF Pharmaceuticals to Hold First Quarter 2022 Financial and Business Results Conference Call on May 11, 2022
TFF Pharmaceuticals Announces Safety and Pharmacokinetic Data from Phase 1 Study of Niclosamide Inhalation PowderApril 19, 2022
TFF Pharmaceuticals Announces Safety and Pharmacokinetic Data from Phase 1 Study of Niclosamide Inhalation Powder
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business UpdateMarch 24, 2022
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
TFF Pharmaceuticals Enters into CRADA with the U.S. Army and The Geneva Foundation to Develop Dry Powder Needle-free Medical CountermeasuresMarch 17, 2022
TFF Pharmaceuticals Enters into CRADA with the U.S. Army and The Geneva Foundation to Develop Dry Powder Needle-free Medical Countermeasures
TFF Pharmaceuticals to Participate at the 34th Annual Roth ConferenceMarch 11, 2022
TFF Pharmaceuticals to Participate at the 34th Annual Roth Conference
TFF Pharmaceuticals to Hold Fourth Quarter and Full Year 2021 Financial and Business Results Conference Call on March 24, 2022March 9, 2022
TFF Pharmaceuticals to Hold Fourth Quarter and Full Year 2021 Financial and Business Results Conference Call on March 24, 2022
TFF Pharmaceuticals and Catalent Announce New Inhalation Dry Powder Development and Manufacturing AgreementMarch 1, 2022
TFF Pharmaceuticals and Catalent Announce New Inhalation Dry Powder Development and Manufacturing Agreement